Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(18/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(18/week)
News
United States
(584/week)
Manufacturing
(404/week)
Energy
(324/week)
Technology
(409/week)
Other Manufacturing
(344/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Androgen deprivation therapy
Jun 03, 2020
Zeulide Depot(TM) is now Covered by the Ontario Drug Benefit (ODB) Program for Patients Living with Prostate Cancer
May 29, 2020
XTANDI® (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis
May 13, 2020
ERLEADA® (apalutamide) Significantly Improved Overall Survival in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Nov 25, 2019
Astellas Announces the Approval of XTANDI® (enzalutamide) by the China National Medical Products Administration (NMPA)
Sep 17, 2019
U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
May 31, 2019
ERLEADA® (apalutamide) Significantly Improved Overall Survival (OS) and Radiographic Progression-Free Survival (rPFS) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
May 05, 2019
Studies Bring Focus To Impact Of Urologic Disease On Mental, Emotional Health
Apr 29, 2019
U.S. FDA accepts New Drug Application and grants Priority Review for darolutamide
Feb 27, 2019
Bayer completes rolling submission of New Drug Application to U.S. Food and Drug Administration for investigational drug darolutamide for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC)
Feb 14, 2019
Bayer's investigational drug darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer
Nov 01, 2018
Combined therapy including pelvic lymph node radiation provides significant benefit for prostate cancer patients
Oct 31, 2018
Men with low- and intermediate-risk prostate cancer can safely benefit from fewer, higher-dose radiation treatments
Oct 24, 2018
Phase III Trial of Darolutamide in Patients with Non-metastatic Castration-resistant Prostate Cancer Meets Primary Endpoint
Sep 24, 2018
Astellas Receives Positive CHMP Opinion for XTANDI® (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
Sep 11, 2018
Health-Related Quality of Life Maintained with Addition of ERLEADA® to Androgen Deprivation Therapy for Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Jul 13, 2018
U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
Jul 04, 2018
Health Canada Approves ERLEADA(TM)* (apalutamide tablets), the First Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer
May 18, 2018
ERLEADA(TM) Significantly Reduced Risk of Prostate Specific Antigen (PSA) Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Feb 15, 2018
Health Canada Approves New Indication for ZYTIGA®* (abiraterone acetate), Broadening its Use for Treatment of Newly Diagnosed Metastatic Prostate Cancer
Feb 14, 2018
ERLEADA(TM) (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Granted U.S. FDA Approval for the Treatment of Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Page 1
››
Latest News
May 14, 2024
Heritage Global Partners and Integra Asset Solutions Host Exclusive Online Auction Featuring Furniture...
May 14, 2024
Traka ASSA ABLOY Americas Awarded GSA Contract for Electronic Key Management Solutions
May 14, 2024
Comvest Partners’ Portfolio Company GAI Consultants Announces Acquisition of Creighton Manning Engineering
May 14, 2024
Maritime Launch Receives Conditional Term Sheet from Government of Canada for Contribution under the...
May 14, 2024
MGE Seeks to Add More Local Solar and Battery Storage to Serve Customers
May 14, 2024
Milliman analysis: Corporate pension funded ratio rises to 103.4% in April despite investment losses
May 14, 2024
Global Energy Harvesting System Industry Research 2024: Market to Reach $1.42 Billion by 2032, Driven by...
May 14, 2024
Eurofins EAG Laboratories Expands Battery Testing Services Supporting Client Acceleration of Battery...
View all News
Agenda
29
October
United Kingdom
Copthorne Tara Hotel, London, UK
International Dismounted Soldier, 29-30 October 2024, Copthorne Tara Hotel, London, UK
Navigating the Evolving Battlespace: Enhancing the Capabilities of the Dismounted Soldier The modern battlefield...
24
September
United Kingdom
Hilton London Syon Park, London, UK
Defence Transformation Conference, 24-26 September 2024, Hilton London Syon Park, London, UK
Returning for its 8th year, Defence Transformation 2024 will feature an updated format that will address all aspects of...
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
View All Events